Publications 2024

Karlsson AT, Hjermstad MJ, Aass N, Skovlund E, Kaasa S, Yri OE (2024)
Overall Survival after Radiotherapy for Brain Metastases According to ECOG Status-A Prospective Study of 294 NSCLC Patients
Cancers (Basel), 16 (8)
DOI 10.3390/cancers16081486, PubMed 38672568

Publications 2022

Winther RR, Hjermstad MJ, Skovlund E, Aass N, Helseth E, Kaasa S, Yri OE, Vik-Mo EO (2022)
Surgery for brain metastases-impact of the extent of resection
Acta Neurochir (Wien), 164 (10), 2773-2780
DOI 10.1007/s00701-021-05104-7, PubMed 35080651

Yri OE, Aass N, Kaasa S (2022)
[Whole brain radiotherapy should be restricted]
Tidsskr Nor Laegeforen, 142 (17)
DOI 10.4045/tidsskr.22.0696, PubMed 36416654

Publications 2021

Gullhaug A, Hjermstad MJ, Yri O, Svestad JG, Aass N, Johansen S (2021)
Use of radiotherapy in breast cancer patients with brain metastases: a retrospective 11-year single center study
J Med Imaging Radiat Sci, 52 (2), 214-222
DOI 10.1016/j.jmir.2021.01.002, PubMed 33549504

Karlsson AT, Hjermstad MJ, Omdahl T, Aass N, Skovlund E, Hellebust TP, Johansen S, Kaasa S, Yri OE (2021)
Overall survival after initial radiotherapy for brain metastases; a population based study of 2140 patients with non-small cell lung cancer
Acta Oncol, 60 (8), 1054-1060
DOI 10.1080/0284186X.2021.1924399, PubMed 34032536

Winther RR, Vik-Mo EO, Yri OE, Aass N, Kaasa S, Skovlund E, Helseth E, Hjermstad MJ (2021)
Surgery for brain metastases - real-world prognostic factors' association with survival
Acta Oncol, 60 (9), 1161-1168
DOI 10.1080/0284186X.2021.1930150, PubMed 34032547

Publications 2016

Daldorff S, Mathiesen RM, Yri OE, Ødegård HP, Geisler J (2016)
Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer
Br J Cancer, 116 (1), 10-20
DOI 10.1038/bjc.2016.405, PubMed 27923036

Publications 2014

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H (2014)
Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma
Leuk Lymphoma, 56 (6), 1742-9
DOI 10.3109/10428194.2014.970550, PubMed 25284491

Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppä S (2014)
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
Haematologica, 100 (2), 238-45
DOI 10.3324/haematol.2014.113472, PubMed 25381134

Publications 2013

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2013)
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
Leuk Lymphoma, 54 (10), 2205-14
DOI 10.3109/10428194.2013.774392, PubMed 23391141

Publications 2012

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2012)
Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
Leuk Lymphoma, 53 (10), 1934-44
DOI 10.3109/10428194.2012.682307, PubMed 22475179

Publications 2011

Randen U, Yri OE, Tierens A, Heim S, Beiske K, Delabie J (2011)
Mantle cell lymphoma with features of marginal-zone lymphoma
J Hematop, 4 (1), 7-11
DOI 10.1007/s12308-011-0084-x, PubMed 25089161

Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundström C, Christensson B, Sander B (2011)
Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
Br J Haematol, 156 (2), 225-33
DOI 10.1111/j.1365-2141.2011.08942.x, PubMed 22126847

Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordøy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A (2011)
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
Blood, 118 (26), 6769-71
DOI 10.1182/blood-2011-08-372649, PubMed 22058114

Publications 2009

Yri OE, Vig J, Hegstad E, Hovde O, Pignon I, Jynge P (2009)
Mangafodipir as a cytoprotective adjunct to chemotherapy--a case report
Acta Oncol, 48 (4), 633-5
DOI 10.1080/02841860802680427, PubMed 19169914

Publications 2005

Yri OE, Bjoro T, Fossa SD (2005)
Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer
Eur Urol, 49 (1), 54-8; discussion 58
DOI 10.1016/j.eururo.2005.09.009, PubMed 16314038

Publications 2003

Mellgren G, Børud B, Hoang T, Yri OE, Fladeby C, Lien EA, Lund J (2003)
Characterization of receptor-interacting protein RIP140 in the regulation of SF-1 responsive target genes
Mol Cell Endocrinol, 203 (1-2), 91-103
DOI 10.1016/s0303-7207(03)00097-2, PubMed 12782406

Publications 1998

Lund J, Jacob A, Aesöy R, Yri OE, Mellgren G (1998)
Biochemical and functional analysis of nuclear receptors as targets in cAMP-dependent control of bovine CYP17
Endocr Res, 24 (3-4), 497-504
DOI 10.3109/07435809809032638, PubMed 9888530